Amylyx Pharmaceuticals(AMLX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

AMLX Amylyx Pharmaceuticals

Pre-Mkt 04-24 08:30:38 EDT

5.06

+0.14

+2.85%

High5.24	Low4.90	Vol1.08M
Open5.07	D1 Closing4.92	Amplitude6.81%
Mkt Cap448.33M	Tradable Cap298.34M	Total Shares88.60M
T/O5.56M	T/O Rate1.84%	Tradable Shares58.96M
P/B2.72	ROE-100.88%	EPS-4.43
52wk High7.27	52wk Low1.58	P/E-1.14
Dividend1.35	Div.Yield0.27	ROA-51.31%

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"AMLX","market":"US","secType":"STK","nameCN":"Amylyx Pharmaceuticals","latestPrice":5.06,"timestamp":1745438400000,"preClose":4.92,"halted":0,"volume":1083152,"delay":0,"floatShares":58959874,"shares":88602468,"eps":-4.43,"marketStatus":"Pre-Mkt","change":0.14,"latestTime":"04-24 08:30:38 EDT","open":5.07,"high":5.235,"low":4.9,"amount":5563706.648527999,"amplitude":0.068089,"askPrice":5.49,"askSize":100,"bidPrice":4.26,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-4.43,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1745501400000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1641531600000,"exchange":"NASDAQ","adjPreClose":5.06,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":5.2333,"preClose":5.06,"latestTime":"18:15 EDT","volume":6594,"amount":33416.228,"timestamp":1745446507263},"volumeRatio":1.214943752520963,"impliedVol":1.3332,"impliedVolPercentile":0.7269},"requestUrl":"/m/hq/s/AMLX/wiki","defaultTab":"wiki","newsList":[{"id":"2526435470","title":"BRIEF-Amylyx Pharma Announces First Participant Dosed In Phase 1, Multiple Ascending Dose Lumina Trial Of Amx0114 In People Living With Amyotrophic Lateral Sclerosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2526435470","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526435470?lang=en_us&edition=full_marsco","pubTime":"2025-04-09 19:01","pubTimestamp":1744196504,"startTime":"0","endTime":"0","summary":"BRIEF-Amylyx Pharma Announces First Participant Dosed In Phase 1, Multiple Ascending Dose Lumina Trial Of Amx0114 In People Living With Amyotrophic Lateral SclerosisApril 9 (Reuters) - Amylyx Pharmace","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250409:nFWN3QM2AQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMLX","BK4007"],"gpt_icon":0},{"id":"2526354472","title":"Amylyx Pharmaceuticals Announces First Participant Dosed in Phase 1, Multiple Ascending Dose Lumina Trial of Amx0114 in People Living With Amyotrophic Lateral Sclerosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2526354472","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526354472?lang=en_us&edition=full_marsco","pubTime":"2025-04-09 19:00","pubTimestamp":1744196412,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250409:nFWN3QM2AQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AMLX","BK4007"],"gpt_icon":0},{"id":"2526354471","title":"Amylyx Pharmaceuticals Inc: Amylyx Expects Early Cohort Data From Lumina This Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2526354471","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526354471?lang=en_us&edition=full_marsco","pubTime":"2025-04-09 19:00","pubTimestamp":1744196412,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250409:nFWN3QM2AQ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AMLX","BK4007"],"gpt_icon":0},{"id":"2526551553","title":"Amylyx Pharmaceuticals Announces First Participant Dosed in Phase 1, Multiple Ascending Dose LUMINA Trial of AMX0114 in People Living with Amyotrophic Lateral Sclerosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2526551553","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526551553?lang=en_us&edition=full_marsco","pubTime":"2025-04-09 19:00","pubTimestamp":1744196400,"startTime":"0","endTime":"0","summary":"- Amylyx expects early cohort data from LUMINA this year. \"AMX0114 targets calpain-2, which has been found to be an important contributor to axonal degeneration and studied over decades of research as a potential target for the treatment of ALS and other neurodegenerative diseases. In preclinical studies, AMX0114 showed improved neuronal survival and reductions in extracellular NfL levels across multiple disease models. We are excited to progress AMX0114 into the clinic for people with ALS as we work to advance a potential therapy for this relentlessly progressive, fatal disease,\" said Camille L. Bedrosian, MD, Chief Medical Officer at Amylyx.\"ALS is a devastating and fatal neurodegenerative disease with limited treatment options, underscoring the urgent need for new therapeutic approaches that target the underlying mechanisms driving ALS progression. AMX0114 represents a potential therapeutic approach to inhibiting one of the fundamental drivers of axonal degeneration,\" said Sabrina P","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/amylyx-pharmaceuticals-announces-first-participant-110000899.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4561","BK4200","AMLX","BK4007","ASO"],"gpt_icon":0},{"id":"2525802498","title":"Amylyx Pharmaceuticals Raised to Outperform From Neutral by Mizuho","url":"https://stock-news.laohu8.com/highlight/detail?id=2525802498","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525802498?lang=en_us&edition=full_marsco","pubTime":"2025-04-08 00:48","pubTimestamp":1744044480,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AMLX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 07, 2025 12:48 ET (16:48 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MFG","AMLX"],"gpt_icon":0},{"id":"2525015138","title":"Mizuho Upgrades Amylyx Pharmaceuticals to Outperform From Neutral, Raises Price Target to $7 From $3","url":"https://stock-news.laohu8.com/highlight/detail?id=2525015138","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525015138?lang=en_us&edition=full_marsco","pubTime":"2025-04-07 18:29","pubTimestamp":1744021794,"startTime":"0","endTime":"0","summary":"Amylyx Pharmaceuticals (AMLX) has an average rating of overweight and mean price target of $8.50, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research f","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MFG","AMLX"],"gpt_icon":0},{"id":"2525092920","title":"Amylyx Pharmaceuticals Inc : Mizuho Raises to Outperform From Neutral; Raises Target Price to $7 From $3","url":"https://stock-news.laohu8.com/highlight/detail?id=2525092920","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525092920?lang=en_us&edition=full_marsco","pubTime":"2025-04-07 17:37","pubTimestamp":1744018631,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250407:nFWN3QL0PT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","AMLX"],"gpt_icon":0},{"id":"2517245951","title":"PSTV Stock Skyrockets on FDA's Orphan Drug Tag for Cancer Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2517245951","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517245951?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 23:58","pubTimestamp":1741363080,"startTime":"0","endTime":"0","summary":"Shares of Plus Therapeutics, Inc. PSTV were up a whopping 311.4% on March 6 after the company announced that the FDA has granted an Orphan Drug Designation  to its lead radiotherapeutic candidate, rhenium  obisbemeda, for treating leptomeningeal metastases  in patients with lung cancer. The stock continued to gain another 51.4% in after-hours trading following the news announcement.The FDA grants ODD to support the development of medicines for rare disorders that affect fewer than 200,000 people in the United States. The ODD makes the sponsor eligible to receive seven years of market exclusivity following a potential approval and tax credit for qualified clinical studies, as well as exemptions from certain FDA application fees, including the Prescription Drug User Fee Act  charge of $4.3 million in 2025.LM is a rare cancer complication in which the primary cancer spreads to the cerebrospinal fluid and leptomeninges that cover the brain and spinal cord.In the past year, shares of Plus T","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pstv-stock-skyrockets-fdas-orphan-155800501.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["XNCR","BK4007","IE00B19Z3581.USD","AMLX","IE0002270589.USD","IE00B19Z3B42.SGD","PSTV","BMRN","BK4139","BK4566","IE00B7SZLL34.SGD"],"gpt_icon":1},{"id":"2517991212","title":"Amylyx Pharmaceuticals Price Target Maintained With a $12.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2517991212","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517991212?lang=en_us&edition=full_marsco","pubTime":"2025-03-05 21:19","pubTimestamp":1741180740,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AMLX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 05, 2025 08:19 ET (13:19 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMLX"],"gpt_icon":0},{"id":"2517689609","title":"Amylyx Pharmaceuticals Faces Challenges in Acquisition Strategy Amid RELYVRIO Discontinuation","url":"https://stock-news.laohu8.com/highlight/detail?id=2517689609","media":"TIPRANKS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517689609?lang=en_us&edition=full_marsco","pubTime":"2025-03-05 14:02","pubTimestamp":1741154532,"startTime":"0","endTime":"0","summary":"Amylyx Pharmaceuticals, Inc. (AMLX) has disclosed a new risk, in the Corporate Activity and Growth category. Amylyx Pharmaceuticals, Inc. faces sig...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/amylyx-pharmaceuticals-faces-challenges-in-acquisition-strategy-amid-relyvrio-discontinuation?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/amylyx-pharmaceuticals-faces-challenges-in-acquisition-strategy-amid-relyvrio-discontinuation?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4023","BK4588","STRK","BK4007","BK4516","BK4596","BK4595","BK4585","AMLX","BK4600"],"gpt_icon":0},{"id":"2517600360","title":"BUZZ-U.S. STOCKS ON THE MOVE-Okta, Natgas companies, UnitedHealth","url":"https://stock-news.laohu8.com/highlight/detail?id=2517600360","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517600360?lang=en_us&edition=full_marsco","pubTime":"2025-03-05 02:46","pubTimestamp":1741114004,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Okta, Natgas companies, UnitedHealthEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newslette","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nL3N3PN1GU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UAL","FITB","WGRX","NVDU","2NVD.UK","ATEC","NVDD","WBA","SNVD.UK","EQT","NEXT","3NVD.UK","DSP","PEPG","HUT","ENPH","AGH","AAL","YMAB","UNH","STIM","ULCC","NVDS","OKTA","PEP","CAPR","AMLX","JBLU","NVIW.SI","CNX","WVE","MDLZ","EVGO","TNYA","SLRN","NVDY","ILMN"],"gpt_icon":1},{"id":"2516089436","title":"Amylyx Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2516089436","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516089436?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 23:18","pubTimestamp":1741101519,"startTime":"0","endTime":"0","summary":"Amylyx Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings SummaryAmylyx Pharmaceuticals Inc AMLX.OQ reported a quarterly adjusted loss of 55 cents per share for the quart","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nL5N3PN1U4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMLX"],"gpt_icon":0},{"id":"2516116672","title":"BUZZ-Amylyx Pharmaceuticals falls on quarterly loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2516116672","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516116672?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 22:37","pubTimestamp":1741099035,"startTime":"0","endTime":"0","summary":"BUZZ-Amylyx Pharmaceuticals falls on quarterly loss** Drug developer Amylyx Pharmaceuticals' AMLX.O shares fall 3.5% to $2.89** Company posts Q4 net loss of $37.5 million compared with net income of $4.7 million a year ago** AMLX closes its underwritten public offering of 19.7 million shares with net proceeds of about $65.5 million** The offering extends the company's cash runway through the end of 2026** In the last 12 months, AMLX has fallen 84%   ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nL3N3PN13H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AMLX"],"gpt_icon":0},{"id":"2516675825","title":"Amylyx files $300M mixed securities shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2516675825","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516675825?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 20:35","pubTimestamp":1741091756,"startTime":"0","endTime":"0","summary":"07:34 EST Amylyx (AMLX) files $300M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving breaking fi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/amylyx-files-300m-mixed-securities-shelf?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/amylyx-files-300m-mixed-securities-shelf?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AMLX","BK4007"],"gpt_icon":0},{"id":"2516867354","title":"Amylyx Pharmaceuticals Inc Files for Mixed Shelf of up to $300 Mln – SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2516867354","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516867354?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 20:31","pubTimestamp":1741091470,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nFWN3PN0FM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AMLX","BK4007"],"gpt_icon":0},{"id":"2516240026","title":"Amylyx Pharma Q4 EPS $(0.55) Misses $(0.52) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2516240026","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516240026?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 19:10","pubTimestamp":1741086642,"startTime":"0","endTime":"0","summary":"Amylyx Pharma (NASDAQ:AMLX) reported quarterly losses of $(0.55) per share which missed the analyst consensus estimate of $(0.52) by 5.77 percent. This is a 885.71 percent decrease over earnings of $0.07 per share from","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44103465/amylyx-pharma-q4-eps-0-55-misses-0-52-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Amylyx Pharma Q4 EPS $(0.55) Misses $(0.52) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMLX"],"gpt_icon":0},{"id":"2516976624","title":"BRIEF-Amylyx Pharmaceuticals Q4 EPS USD -0.55","url":"https://stock-news.laohu8.com/highlight/detail?id=2516976624","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516976624?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 19:00","pubTimestamp":1741086045,"startTime":"0","endTime":"0","summary":"BRIEF-Amylyx Pharmaceuticals Q4 EPS USD -0.55\n\n\nMar 04 (Reuters) - Amylyx Pharmaceuticals Q4 net income USD -37.546 million.\n\nQ4 operating income USD -40.654 million\nQ4 pretax profit USD -38.181 million\nQ4 operating expenses USD 39.989 million\nQ4 cash & investments USD 176.5 million","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nPLXA36C69:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMLX"],"gpt_icon":0},{"id":"2516624978","title":"Amylyx Pharmaceuticals Inc - Expected Cash Runway Through End of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2516624978","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516624978?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 19:00","pubTimestamp":1741086001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nPLXA36C69:7","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AMLX","BK4007"],"gpt_icon":0},{"id":"2516624955","title":"Amylyx Pharmaceuticals Q4 EPS USD -0.55","url":"https://stock-news.laohu8.com/highlight/detail?id=2516624955","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516624955?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 19:00","pubTimestamp":1741086001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nPLXA36C69:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AMLX","BK4007"],"gpt_icon":0},{"id":"2516262783","title":"Press Release: Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2516262783","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516262783?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 19:00","pubTimestamp":1741086000,"startTime":"0","endTime":"0","summary":"-- Pivotal Phase 3 LUCIDITY trial of avexitide, a potential first-in-class. completion of recruitment expected in 2025, with topline data anticipated. \"We made significant progress in 2024 across our pipeline, setting the stage for important milestones in the year ahead in orphan markets with high unmet need. We advanced our lead investigational asset avexitide into a pivotal Phase 3 trial and expect topline results in the first half of 2026. This year, we anticipate Week 48 data from our AMX0035 program in Wolfram syndrome, interim analysis data from our AMX0035 program in PSP, and early cohort data from our AMX0114 program in ALS,\" said Joshua Cohen and Justin Klee, Co-CEOs of Amylyx. \"With a strong balance sheet, strengthened by our recent financing that extended our expected cash runway through the end of 2026, we believe we are well positioned to achieve our goals.\". glucagon-like peptide-1  receptor antagonist, for the treatment of. safety of avexitide in participants with PBH fo","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMLX","BK4200","BK4232","PSP","PBH","BK4022","BK4099","BK4555","BK4604","R","BK4585","TM","ASO","BK4588","BK4007","03160","BK4561"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.amylyx.com","stockEarnings":[{"period":"1week","weight":0.3246},{"period":"1month","weight":0.3386},{"period":"3month","weight":0.4213},{"period":"6month","weight":-0.0471},{"period":"1year","weight":1.5949},{"period":"ytd","weight":0.3386}],"compareEarnings":[{"period":"1week","weight":0.0186},{"period":"1month","weight":-0.0673},{"period":"3month","weight":-0.1219},{"period":"6month","weight":-0.0753},{"period":"1year","weight":0.0589},{"period":"ytd","weight":-0.0864}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.037729},{"month":2,"riseRate":0.5,"avgChangeRate":0.096144},{"month":3,"riseRate":0.25,"avgChangeRate":-0.384218},{"month":4,"riseRate":0.25,"avgChangeRate":-0.066237},{"month":5,"riseRate":0,"avgChangeRate":-0.064193},{"month":6,"riseRate":0.666667,"avgChangeRate":0.381588},{"month":7,"riseRate":1,"avgChangeRate":0.190906},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.022589},{"month":9,"riseRate":0.666667,"avgChangeRate":0.141337},{"month":10,"riseRate":0.666667,"avgChangeRate":0.274859},{"month":11,"riseRate":0.666667,"avgChangeRate":-0.010067},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.10505}],"exchange":"NASDAQ","name":"Amylyx Pharmaceuticals","nameEN":"Amylyx Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Amylyx Pharmaceuticals(AMLX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Amylyx Pharmaceuticals(AMLX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Amylyx Pharmaceuticals,AMLX,Amylyx Pharmaceuticals股票,Amylyx Pharmaceuticals股票老虎,Amylyx Pharmaceuticals股票老虎国际,Amylyx Pharmaceuticals行情,Amylyx Pharmaceuticals股票行情,Amylyx Pharmaceuticals股价,Amylyx Pharmaceuticals股市,Amylyx Pharmaceuticals股票价格,Amylyx Pharmaceuticals股票交易,Amylyx Pharmaceuticals股票购买,Amylyx Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Amylyx Pharmaceuticals(AMLX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Amylyx Pharmaceuticals(AMLX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction